UK markets closed

Regulus Therapeutics Inc. (RGLS)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
2.2300-0.0300 (-1.33%)
As of 03:06PM EDT. Market open.

Regulus Therapeutics Inc.

4224 Campus Point Court
Suite 210
San Diego, CA 92121
United States
858 202 6300
https://www.regulusrx.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 30

Key executives

NameTitlePayExercisedYear born
Mr. Joseph P. Hagan M.B.A.CEO & Director958.23kN/A1969
Ms. Crispina Calsada CPAChief Financial Officer579.3kN/A1970
Mr. Christopher Ray Aker J.D.Senior VP, General Counsel & Corporate Secretary575.94kN/A1961
Dr. Preston S. Klassen M.D., M.H.S.President, Head of Research & Development and DirectorN/AN/A1969
Mr. Daniel J. PenksaVP of Finance & ControllerN/AN/A1986
Dr. Claire Susan Padgett M.S., M.T., Ph.D.Senior Vice President of Clinical OperationsN/AN/AN/A
Dr. Rekha Garg M.D., M.S.Senior Vice President of Clinical Development & RegulatoryN/AN/AN/A
Mr. Edmund Lee Ph.D.Vice President of Translational MedicineN/AN/AN/A
Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Regulus Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RGLS8429, an anti-miR next generation oligonucleotide targeting miR-17, which is in Phase 1b clinical trial for the treatment of autosomal dominant polycystic kidney disease. The company is also developing a pipeline of preclinical drug products for target organ-selective delivery strategies. Regulus Therapeutics Inc. was incorporated in 2007 and is headquartered in San Diego, California.

Corporate governance

Regulus Therapeutics Inc.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.